Thesis
Alpha DaRT's ReSTART PMA readout will determine whether a novel brachytherapy platform earns its first U.S. regulatory foothold across a multi-indication strategy
Alpha DaRT is an intratumoral alpha-emitting brachytherapy device targeting recurrent cutaneous squamous cell carcinoma in its U.S. pivotal ReSTART trial, with parallel programs in recurrent GBM, pancreatic cancer, and approved use in head and neck cancer in Japan. The thesis resolves on whether ReSTART meets its co-primary ORR and DOR endpoints sufficient for FDA PMA, validating the platform's regulatory pathway across indications. Primary risk is that conventional external beam radiotherapy and PD-1 inhibitors such as cemiplimab are already established in cSCC, setting a demanding efficacy and durability bar the device must clear in a single-arm study without a randomized comparator.
Focus
ReSTART pivotal trial primary endpoint data readout
year-end 2026
Bull
A positive readout would demonstrate a compelling confirmed ORR alongside durable responses (DOR ≥6 months) in recurrent cutaneous squamous cell carcinoma, providing the clinical evidence required to complete the PMA filing and support FDA approval. U.S. approval would de-risk the broader platform, accelerate label expansion discussions, and significantly strengthen the commercial infrastructure being built with Tolmar, establishing a U.S. revenue base and credibility for the pancreatic and glioblastoma programs.
Bear
The most likely failure modes are an ORR that falls below the prespecified threshold, or responses that are insufficiently durable with DOR at six months failing to meet the co-primary endpoint benchmark. Given that recurrent cSCC patients are often heavily pretreated and may have limited residual immune function, poor local tumor control or high rates of early progression could undermine both endpoints simultaneously; any signal of unexpected late toxicity from the alpha-emitting seeds could further complicate the benefit-risk assessment for FDA reviewers.
Unlock the full thesis for DRTS.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.